CND Life Sciences

Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Phoenix, Arizona, CND launched the Syn-One Test™ as the world’s first commercially available test to detect, visualize, and quantify the presence of abnormal proteins in nerve fibers of the skin. The test is intended to serve as an objective, evidence-based diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease, dementia with Lewy body, and other serious neurological disorders. Through proprietary laboratory analysis of small punch skin biopsies performed and provided by a referring clinician, CND offers a convenient, accurate, minimally invasive alternative to add clarity and confidence in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and was awarded a prestigious NIH SBIR grant in 2020 to advance its testing technology. For more information visit www.cndlifesciences.com.